ClinicalTrials.gg
RecruitingNCT03830320Updated Feb 27, 2026

Positron Emission Tomography (PET) Imaging of Thrombosis

A Phase 1 interventional study of [64Cu]FBP8 and PET/MR in Atrial Fibrillation, COVID-19 and Cancer, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Massachusetts General Hospital · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Apr 2016, registered Jan 2019).
  • Started Apr 2016; still recruiting 10 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
165
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Atrial Fibrillation by Massachusetts General Hospital — 4 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Massachusetts General Hospital.

Planned enrollment
7th of 13
165 · median 165
Started
2016
the only one that year
Phase 1
Only one
of the 15
Registered
9th of 15
by date

Among the 15 studies in Atrial Fibrillation by Massachusetts General Hospital, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 1, and was the 9th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 15 studies in Atrial Fibrillation by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Atrial Fibrillation by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Read the detailed description

The primary objectives of this study are:

  1. To evaluate the safety of [64Cu]FBP8 and its whole body distribution, metabolism, pharmacokinetics, and radiation burden in healthy volunteers.
  2. To establish the accuracy of [64Cu]FBP8 -PET to detect left atrial thrombosis in patients with atrial fibrillation.
  3. To explore the feasibility of [64Cu]FBP8 -PET to detect thrombosis in patients with COVID-19.
  4. To explore the feasibility of [64Cu]FBP8 -PET to detect thrombosis in patients with cancer.
  5. To explore the feasibility of [64Cu]FBP8 -PET to detect thrombosis in patients with known or suspicion of thrombus outside of the left atrial appendage.
03

Conditions studied

  • Atrial Fibrillation
  • COVID-19
  • Cancer
  • Thrombosis

Keywords

  • PET-MRI
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For Atrial Fibrillation Patient subjects:

  • History of atrial fibrillation or paroxysmal atrial fibrillation;
  • Retrospective enrollment: TEE to evaluate LAA within the last 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE and continues the same stable anti-coagulation regimen he/she is on, then it is extremely unlikely that a new thrombus will develop in the left atrial appendage within the next two weeks. Likewise, if a patient not taking any anti-coagulation has a thrombus in the left atrial appendage, then it is extremely unlikely that this thrombus will resolve spontaneously in the next 14 days if the patient continues not to take any anticoagulation. If the TEE leads to a change being made in the anticoagulation regimen (started/stopped/dose modified), then a time window of 72 hours from the TEE to PET imaging will be used. This scheme will ensure that the TEE can serve as an accurate gold standard;
  • Prospective enrollment: TEE to evaluate LAA scheduled in upcoming 14 days;

For COVID-19 Patient subjects:

  • Positive test for SARS-CoV-2 RNA detected by RT-PCR collected from the upper or lower respiratory tract analyzed by a certified lab with an FDA approved assay within the last month;
  • Patient not requiring mechanical ventilation;

For Cancer Patient subjects:

  • Patient is diagnosed with cancer;

For Other Patient subjects:

  • Ultrasound- or CT-confirmed or high likelihood of thrombus (e.g., elevated D-dimer)
  • Has not received thrombolytics

Exclusion criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Subjects less than 18 years of age;
  • Electrical implants such as cardiac pacemaker or perfusion pump;
  • Pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required for females having before the subject can participate);
  • Claustrophobic reactions;
  • Subjects will be excluded if research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);
  • Unable to lie comfortably on a bed inside the PET scanner;
  • Subjects under direct or indirect (i.e. same department as PIs) supervision of the principal investigator;
  • Body weight over the weight limit for the moving table (> 300 lbs for the MRI table and >441 lbs for the CT table);
  • Metallic or electric implants for MR-PET scanning when applicable;
  • Does not have the ability to give written .
  • Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures);

Additional exclusion criteria for Atrial Fibrillation Patient subjects:

  • Stroke within the last 3 months;
  • Myocardial infarction within the last 3 months;
  • Cardiac or major surgery within the last 3 months;
  • History of chest pain within the last 6 weeks unless followed by a subsequent stress test or coronary angiography;
  • History of syncope within the last 6 weeks;
  • Heart rate persistently >120 bpm or persistently \< 50 bpm;
  • Presence of daytime pauses > 3s
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Active comparator
    Healthy Volunteers

    Twenty (20) healthy adult subjects will be injected with \[64Cu\]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.

    Drug: [64Cu]FBP8 · Device: PET/MR · Procedure: Blood Collection · Procedure: Electrocardiogram

  • Experimental
    Atrial Fibrillation Patients

    Thirty-five (35) patients with LAA thrombus documented by TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care. Thirty-five (35) patients with atrial fibrillation and negative TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus. Forty (40) patients with atrial fibrillation who are scheduled for TEE in the upcoming 14 days will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus.

    Drug: [64Cu]FBP8 · Device: PET/MR

  • Experimental
    COVID-19 Patients

    Thirty (30) COVID-19 patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.

    Drug: [64Cu]FBP8 · Device: PET/MR

  • Experimental
    Cancer Patients

    Thirty (30) cancer patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.

    Drug: [64Cu]FBP8 · Device: PET/MR

  • Experimental
    Other Thrombotic Condition Patients

    Fifty (50) patients with other thrombotic conditions will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.

    Drug: [64Cu]FBP8 · Device: PET/MR

Interventions

  • DrugCopper Cu 64 FBP8Studies of Copper Cu 64 FBP8Copper Cu 64 FBP8 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection of Copper-64 radiopeptide to detect thrombosis

    Also known as: 64Cu-FBP8

  • DevicePET/MR

    Whole body imaging using Siemens mMR PET/MR scanner

    Also known as: PET-MR

  • ProcedureBlood Collection

    A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry

  • ProcedureElectrocardiogram

    A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer

    Also known as: ECG

06

What researchers measure

Primary outcomes

  1. Complete blood count

    To model pharmacokinetics of \[64Cu\]FBP8 metabolism in healthy volunteers.

    Time frame: 36 hours

  2. Target to Background Ratio LAA

    To determine the signal threshold of \[64Cu\]FBP8 that produces the highest accuracy of \[64Cu\]FBP8 -PET to detect left atrial thrombosis in patients with atrial fibrillation.

    Time frame: 4 hours

  3. Target to Background Ratio

    To determine the signal threshold of \[64Cu\]FBP8 that produces the highest accuracy of \[64Cu\]FBP8 -PET to detect thrombosis in patients with known thrombus or suspicion of thrombus.

    Time frame: 4 hours

  4. Time activity curve

    To evaluate human dosimetry and radiation burden in healthy volunteers.

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Izquierdo-Garcia D, Desogere P, Philip AL, Mekkaoui C, Weiner RB, Catalano OA, Iris Chen YC, DeFaria Yeh D, Mansour M, Catana C, Caravan P, Sosnovik DE. Detection and Characterization of Thrombosis in Humans Using Fibrin-Targeted Positron Emission Tomography and Magnetic Resonance. JACC Cardiovasc Imaging. 2022 Mar;15(3):504-515. doi: 10.1016/j.jcmg.2021.08.009. Epub 2021 Oct 13. PubMed 34656469 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2016 (actual). Primary completion is estimated for Jan 2027, 129 months after the start.

Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 129 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Feb 5, 2019
StartActual
Apr 1, 2016
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03830320
Responsible party
Peter Caravan (Professor of Radiology, Massachusetts General Hospital) — Principal investigator
First posted
Feb 5, 2019
Start date
Apr 1, 2016
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

David E Sosnovik, MD
Contact
sosnovik@nmr.mgh.harvard.edu
617-724-3407
Anne L Philip, MPH
Contact
alphilip@mgh.harvard.edu
617-726-0431
Ciprian Catana, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copper Cu 64 FBP8

Start the discussion